This was on the cards sorry to say,we could see this coming shee........it's sick!
I bet if all kids have to have it,there will be more than 2000 deaths as a direct result from some of the vaccines!
They're going to give kids the nasal spray,probly made by
AstraZenica
FluMist is a nasal spray influenza vaccine manufactured by MedImmune, Inc. that was first introduced in 2003.[1] It was the first and (as of 2007) the only live attenuated vaccine for influenza available outside of Europe.[2] It is also called live attenuated influenza vaccine (LAIV).[3] In September 2009 a LAIV intranasal vaccine for the novel H1N1 influenza virus was approved.[4] In 2011, the vaccine was approved by the European Medicines Agency for use in the European Union under the name Fluenz.
So lets take a quick look at AstraZenica
History
Astra AB was founded in 1913 in Södertälje, Sweden by 400 doctors and apothecaries.[8] In 1993 the British chemicals company ICI demerged its pharmaceuticals businesses and its agrochemicals and specialties businesses, to form Zeneca Group plc,[9] and in 1999 Astra and Zeneca Group merged to form AstraZeneca plc.[9]
In 2005 the company announced that it had become a Diamond Member of the Pennsylvania Bio commerce organization.[10] It also decided to acquire KuDOS Pharmaceuticals, a UK biotech company, for £120m[11] and entered into an anti-cancer collaboration agreement with Astex.[12]
In 2006, following a collaborative relationship begun in 2004, AstraZeneca acquired Cambridge Antibody Technology for £702 million.[13]
In February 2007 AstraZeneca agreed to buy Arrow Therapeutics, a company focused on the discovery and development of anti-viral therapies, for $150 million.[14]
AstraZeneca's pipeline, and 'patent cliff', was the subject of much speculation in April 2007 leading to pipeline-boosting collaboration and acquisition activities.[15] A few days later AstraZeneca acquired American company MedImmune for about $15.2 billion; AstraZeneca subsequently consolidated all of its biologics operations into a dedicated biologics division known as 'MedImmune'.[16]
In 2011 AstraZeneca acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business.[17]
In February 2012 AstraZeneca and Amgen announced collaboration on treatments for inflammatory diseases.[18] Then in April 2012, AstraZeneca acquired Ardea Biosciences, another biotechnology company, for $1.26 billion.[19]
In June 2012 AstraZeneca and Bristol-Myers Squibb announced a two-stage deal for the joint acquisition of the biotechnology company Amylin Pharmaceuticals.[20][21] It was agreed that Bristol-Myers Squibb would acquire Amylin for US$5.3 billion in cash and the assumption of $1.7 billion in debt, with AstraZeneca then paying US$3.4 billion in cash to Bristol-Myers Squibb, and Amylin being folded into an existing diabetes joint-venture between AstraZeneca and Bristol-Myers Squibb.[21]
[edit] Operations
AstraZeneca develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas.
AstraZeneca has its corporate headquarters in London, United Kingdom and its research and development (R&D) headquarters are in Södertälje, Sweden. The company employs over 11,000 people at research facilities in the United Kingdom, United States, Sweden, France, Canada, India, China and Japan.
The company's largest single research and development site is at Alderley Park (a large country estate on the east side of the A34 road north of the Monk's Heath crossroads) in Cheshire, England. Around 4,500 staff are based at the site.[22]
The company has a major research and development presence in Sweden, with approximately 4,000 staff employed at research facilities in Mölndal and Södertälje.[23]
[edit] Products
AstraZeneca specialises in prescription medicines to fight disease in several therapeutic areas. The following is a list of key products found on the AstraZeneca website.[24] Generic- drug names are given in parentheses following the brand name.
This list is incomplete; you can help by expanding it.
– Anaesthetics
Carbocaine (mepivacaine)
Citanest (prilocaine)
Diprivan (propofol)
EMLA (lidocaine/prilocaine)
Marcaine and Sensorcaine (bupivacaine)
Naropin (ropivacaine)
Xylocaine (lidocaine)
Xyloproct (lidocaine/hydrocortisone)
-Cardiovascular
Atacand (candesartan cilexetil)
Betaloc (metoprolol)
Brilinta (ticagrelor)
Crestor (rosuvastatin; 2003 launch)
Exanta (ximelagatran; 2004 launch; not approved in the U.S., now withdrawn)
Imdur (isosorbide mononitrate)
Inderal (propranolol)
Lexxel (enalapril/felodipine
Logimax (felodipine/metoprolol
Nif-Ten (nifedipine/atenolol)
Plendil (felodipine)
Ramace (ramipril)
Seloken XL and Toprol-XL (metoprolol;
Tenoretic (atenolol/chlortalidone)
Tenormin (atenolol)
Unimax (felodipine/ramipril)
Zestoretic (lisinopril/hydrochlorothiazide)
Zestril (lisinopril)
-Gastrointestinal
Entocort (budesonide)
Losec and Prilosec (omeprazole)
Nexium (esomeprazole; S-stereoisomer of Losec)
Vimovo (naproxen/esomeprazole)
– Infection
Apatef and Cefotan (cefotetan)
Avloclor (chloroquine)
Cubicin (daptomycin)
Paludrine (proguanil)
Foscavir (foscarnet)
Lexinor (norfloxacin)
Merrem and Meronem (meropenem)
-Neuroscience
Heminevrin (clomethiazole)
Mysoline (primidone; handed over to Acorus Therapeutics Ltd. in July 2004)
Seroquel (quetiapine)
Seroquel XR ([quetiapine extended release])
Vivalan (viloxazine)
Zomig (zolmitriptan)
-Oncology
Arimidex (anastrozole)
Casodex (bicalutamide)
Faslodex (fulvestrant)
Iressa (gefitinib)
Nolvadex (tamoxifen)
Tomudex (raltitrexed)
Zoladex (goserelin)
Caprelsa (vandetanib)
in development[clarification needed] Recentin (cediranib)
-Respiratory and Inflammation
Accolate (zafirlukast)
Bambec (bambuterol)
Bricanyl (terbutaline)
Oxis (formoterol)
Pulmicort, Rhinocort (budesonide)
Symbicort (budesonide/formoterol)
[edit] Senior management
The senior executive team is composed of David Brennan, Simon Lowth, John Patterson, Tony Zook, David Mott, Bruno Angelici, Lynn Tetrault and David Smith. As of 2008, Brennan is paid $1,574,144 for his role as chief executive officer.[25]
On 26 April 2012, it was announced that David Brennan was to retire early in the June of that year[26]
It was also announced that Leif Johansson will succeed Louis Schweitzer as Non-Executive Chairman on 1 June 2012 – three months earlier than previously announced – and will become Chairman of the Nomination and Governance Committee after (the 2012) Annual General Meeting."[26]
[edit] Controversies
[edit] Seroquel: adverse effects and trial procedures
AstraZeneca has stated that the atypical-antipsychotic drug, Seroquel, is the subject of four class-action lawsuits in Canada. Also, in the U.S., there were multiple product-liability cases alleging personal injury, namely, that Seroquel caused people to develop diabetes.
The company has indicated its intention to seek approval for Seroquel to treat psychiatric conditions such as depression and general anxiety disorder.[27]
Note as well that scientific findings regarding a new sustained-release form of the drug were announced at a conference in Madrid, Spain, in March 2007. At the time the data regarding the new drug were discussed, the drug had not been approved for sale by any health regulatory body in any country.[28]
During 2005 and 2006 clinical trials were carried out to examine the possibilities of further development of Seroquel. Test persons were recruited from research centres in Russia, Ukraine, Poland, Bulgaria and India. As part of the trials half of the test persons were given a placebo and stopped their medication. As a result thirty-six test persons relapsed into illness. One test person committed suicide, possibly as a result of quitting his medication. AstraZeneca denied that the suicide was related to the testing procedures. Ethical concerns were raised over the issue of carrying out trials in less-developed countries because of lower requirements for getting trials approved and overall lower trial costs.
In 2008, 45% of the test persons in AstraZeneca medical trials came from Asia; Eastern- and Central Europe; and South America. The same year 13.5% of the total sales were made in these regions. In contrast 86% of total sales were made in Japan, North America and Western Europe.[29]
In April 2010 AstraZeneca settled a Qui Tam lawsuit brought by Stefan P. Kruszewski for $520 million to settle allegations that the company defrauded Medicare, Medcaid and other government-funded health care programs in connection with its marketing and promotional practices for the blockbuster atypical antipsycotic Seroquel.[30]
In March 2011, AstraZeneca settled a lawsuit in the United States totaling $68.5 million dollars to be divided up to 38 states.[31] Claims were made against AstraZeneca that it promoted Seroquel's use in children and adolescents long before establishing that it was safe or effective for any use in this population. Furthermore, it was found that patients experienced very serious side effects, including weight gain, diabetes and heart problems. AstraZeneca has been caught in a number of lawsuits stemming from deceptive and unfair promotion of Seroquel, and this is not the first series of settlements.[32]
[edit] Late-stage trial failures
Recently, AstraZeneca has experienced a run of failures of drugs in late-stage clinical trials.[33] These include Galida for diabetes, and Exanta to prevent thrombosis. Other drugs with late-failing trials include NXY-059[34] for acute ischemic stroke, Iressa for lung cancer, and AGI-1067 for prevention of atherosclerosis. With patents expiring on older drugs, this threatens future revenue growth.
[edit] MedImmune takeover
After this long run of failed late-stage clinical trials, on 19 June 2007 AstraZeneca completed the acquisition of vaccine maker MedImmune, paying $15.2 billion primarily for its drug-development pipeline. Analysts have criticised this take-over, claiming that AstraZeneca paid too much.[35] AstraZeneca consolidated its biologics portfolio in MedImmune and Cambridge Antibody Technology (acquired in 2007).[36] This biologics portfolio was then rebranded to create a dedicated, global biologics organisation known as 'MedImmune'. Amid allegations of broken promises over this consolidation,[36] AstraZeneca presented the new MedImmune to investors on 7 December 2007.[16]
en.wikipedia.org/wiki/AstraZenecaAnd thats only from wiki,i will be digging deeper!
Happy New Years Everybody!!!
